September 28, 2022
BURLINGTON, Ontario – September 29, 2022 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, is one of five Canadian companies accepted into this year’s Venture Mentoring Services program offered by the Maryland Tech...
September 23, 2022
BURLINGTON, Ontario – September 23, 2022 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company focused on health and wellness leveraging an innovative, proprietary oral delivery platform today announced that they have entered into a supplier and purchase agreement...
September 12, 2022
BURLINGTON, Ontario – September 12, 2022 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, announces that further to its press release dated August 29, 2022, the Company and its auditors are continuing to...
August 25, 2022
Rapid Dose Therapeutics Provides Bi-Weekly MCTO Status Update BURLINGTON, Ontario – August 25, 2022: Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, is providing a bi-weekly default status update in accordance with National Policy...
August 11, 2022
Rapid Dose Therapeutics Provides Bi-Weekly MCTO Status Update BURLINGTON, Ontario – August 11, 2022: Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, is providing a bi-weekly default status update in accordance with National Policy...
August 10, 2022
Rapid Dose Therapeutics Announces Closing of First Tranche of Private Placement BURLINGTON, Ontario – August 10, 2022: Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, today announced that it has closed on $230,000 in...
July 28, 2022
Rapid Dose Therapeutics Provides Bi-Weekly MCTO Status Update BURLINGTON, Ontario – July 28, 2022: Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, is providing a bi-weekly default status update in accordance with National Policy...
July 13, 2022
Rapid Dose Therapeutics Provides Bi-Weekly MCTO Status Update BURLINGTON, Ontario – July 13, 2022: Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, is providing a bi-weekly default status update in accordance with National Policy 12-203...
June 30, 2022
BURLINGTON, Ontario – June 30, 2022: Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, announces that, further to its press release dated June 16, 2022 (the “Default Announcement”), at the request of the Company, the...
June 16, 2022
Rapid Dose Therapeutics Announces Delay in Filing Annual Financial Statements BURLINGTON, Ontario – June 16, 2022: Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, announces that it will not be in a position to file...